Already have a subscription?Sign In
Access All Charts and Data
Access All Charts and Data
Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.
April 26, 2023
Leading Reasons That US Patients With Obesity Aren't Trying GLP-1s*, March 2023 (% of respondents)
Featured In
Hims & Hers launches a weight loss program without GLP-1 obesity drugs—for now Mayo Clinic enhances its weight loss program with access to obesity drugsNestlé shifts gears as consumers embrace weight-loss drugsExpanding uses for weight-loss meds could fuel salesHealth plans will cover Wegovy for heart diseaseCostco’s direct-to-consumer healthcare service now includes access to weight loss drugs Wave of new obesity drugs to launch in US in next 5 yearsFTC cracking down on “junk” drug patentsVitamin Shoppe launches telehealth service for GLP-1sNestlé prepares for the Ozempic effectChart Title
Leading Reasons That US Patients With Obesity Aren't Trying GLP-1s*, March 2023 (% of respondents)Publication Date
April 26, 2023
Sources
Source information is only available to PRO subscribers.